Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis
This study will assess the efficacy and safety of MBP8298 compared to placebo in subjects with Secondary Progressive Multiple Sclerosis (SPMS)
Multiple Sclerosis, Secondary Progressive
DRUG: MBP8298
Time to progression of disease in subjects with SPMS as measured by the EDSS after 24 months of treatment, 24 Months
To assess the safety of MBP8298, degree of change in the EDSS scores, effect of MBP8298 on MRI parameters, difference in relapse rates, effect on MSFC, subject's quality of life (MSQoL54) and fatigue (MFIS) after 24 months of treatment, 24 Months
This study will assess the efficacy and safety of MBP8298 compared to placebo in subjects with Secondary Progressive Multiple Sclerosis (SPMS)